Titan Medical to Present at the H.C. Wainwright Global Investment Conference
06 September 2022 - 9:30PM
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology
company focused on single access robotic-assisted surgery (RAS)
system, today announced the company will present an overview of its
Enos™ robotic single access surgical system at the H.C. Wainwright
Global Investment Hybrid Conference, taking place September 12-14,
2022 at the Lotte New York Palace Hotel in New York, NY, and
virtually.
Cary Vance, Titan’s President and Chief
Executive Officer will provide a company overview and participate
in investor meetings with Stephen Lemieux, Titan’s Chief Financial
Officer, and Kristen Galfetti, Vice President of Investor Relations
and Corporate Communications.
Titan Medical’s presentation will be available
on-demand September 12th at 7:00 am ET, and available via webcast
and replay on the Investor Relations Events section of the
company’s website at
https://ir.titanmedicalinc.com/news-events/ir-calendar.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a
medical device company headquartered in Toronto, Ontario and with
operations in Chapel Hill, North Carolina, is focused on enhancing
robotic assisted surgery using innovative technology through a
single access point. The Enos™ robotic single access surgical
system is being developed with an ergonomic focus to provide a
surgical experience that imitates real-life movements that surgeons
demand and includes multi-articulating instruments designed to
allow surgeons an increased range of motion in a confined space,
with dexterity and the ability to exert the forces necessary to
complete common surgical tasks. With the Enos system, Titan intends
to initially pursue gynecologic surgical indications.
Enos™ is a trademark of Titan Medical Inc.
For more information,
visit www.titanmedicalinc.com and
follow @TitanMedical on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws, which
reflect the current expectations of management of the company’s
future growth, results of operations, performance and business
prospects and opportunities. Forward-looking statements are
frequently, but not always, identified by words such as “may”,
“would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions, although these words may not be present in all
forward-looking statements. Forward-looking statements that appear
in this release may include, without limitation, references to: the
company’s focus on the development of surgical technologies for
robotic single access surgery; the Enos system providing a surgical
experience that imitates real-life movements; the company’s
intention to initially pursue gynecologic surgical indications with
the Enos system. These statements reflect management’s current
beliefs with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the company’s Annual
Report for the fiscal year ended December 31, 2021 (which may be
viewed at www.sedar.com and at www.sec.gov). Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
ContactKristen GalfettiVice President, Investor
Relations & Corporate
Communications+1-781-869-2553investors@titanmedicalinc.com
###
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From May 2023 to May 2024